Abstract:Drug-induced hypersensitivity syndrome (DIHS), or drug rash with eosinophilia and systemic symptoms, is a severe adverse drug reaction. Diagnostic criteria for DIHS include rash, fever, lymphadenopathy, hematological abnormality, history of causative drug administration, internal organ involvement, and activation of human herpes virus 6 (HHV-6). A 71-year-old female had been treated with mexiletine for arrhythmia 24 days prior to the occurrence of skin rash. She was referred to our hospital with a generalized maculopapular rash and periorbital/facial edema studded with pinhead-sized pustules (Fig. 1a) for 17 days, and intermittent fever, edema, and general fatigue for 10 days. Physical examinations revealed erosion on oral mucosa and axillary lymphadenopathy. Laboratory findings showed hyperglycemia (466 mg/dl), normal glycosylated hemoglobin A1c (6.0%), low serum C-peptide levels (<0.05 ng/ml), and negative diabetes-related antibody titers for islet cell, insulinoma-associated protein-2, and glutamic acid decarboxylase. Both antinuclear antibody (47.1; normal, <9.9) and anti-Sjögren’s syndrome A antibody (104.4; normal, <19.9) indexes were elevated. The titer of anti-cytomegalovirus (CMV) IgM index was elevated (1.79; normal, <0.8; Table 1). Skin biopsy on the trunk demonstrated infiltrations of lymphocytic cells in the epidermis with dyskeratotic cells, liquefaction, and perivascular infiltrations of lymphocytic cells in the dermis (Fig. 1b). Accordingly, we diagnosed the patient with DIHS in conjunction with fulminant type 1 diabetes mellitus. We discontinued medication and initiated systemic corticosteroid administration (prednisolone, 60 mg daily) and subcutaneous insulin injection therapy, which controlled DIHS and diabetes. Twenty-eight days after the onset of skin eruption, the patient exhibited elevated levels of anti-thyroglobulin (5.1 U/ml; normal, <0.299) and antimicrosomal antibodies (44.3 U/ml; normal, <0.299), and decreased levels of free triiodothyronine (1.23 pg/ml; normal, 2.97–4.51) and free thyroxine (0.72 ng/dl; normal, 0.81–1.58). These findings suggested a diagnosis of Hashimoto’s thyroiditis; accordingly, daily administration of 25 mg sodium levothyroxine was initiated. On the 72nd day after onset of skin rash, an elevated titer of anti-HHV-6-IgG (1 : 160) compared with that measured 355

Comment on ‘Drug reaction with eosinophilia and systemic symptoms syndrome in a patient with COVID‐19’: involvement of herpesvirus reactivations and adverse drug reactions in diverse cutaneous manifestations and overall disease severity of COVID‐19

Current Perspective Regarding the Immunopathogenesis of Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms (DIHS/DRESS)

Sulfasalazine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) coinfected with COVID-19 complicated by hemophagocytic lymphohistiocytosis: a case report

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System

Advances in understanding of the pathogenesis and therapeutic implications of drug reaction with eosinophilia and systemic symptoms: an updated review

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome and Myocarditis: A Case Report and Literature Review on Fatal Complications of Reactivated Viral Infections

DRESS syndrome with multiorgan involvement and HHV‐6 reactivation in the absence of a drug trigger

Drug Reaction with Eosinophilia and Systemic Symptoms Associated with Reactivation of Epstein-Barr Virus and/or Cytomegalovirus Leading to Hemophagocytic Syndrome in One of Two Patients.

Viral reactivation and clinical outcomes in Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

Late‐onset interstitial nephritis in a patient with drug‐induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms

Sildenafil-induced drug reaction with eosinophilia and systemic symptoms

Updates and Insights in the Diagnosis and Management of DRESS Syndrome

Monocytes are involved in the balance between regulatory T cells and Th17 cells in severe drug eruptions

Drug‐induced hypersensitivity syndrome complicated with concurrent fulminant type 1 diabetes mellitus and Hashimoto’s thyroiditis

Drug-induced hypersensitivity syndrome related to piperacillin-tazobactam: a case report and review of the literature

Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS): How Far Have We Come?

Variation of clinical manifestations according to culprit drugs in DRESS syndrome

Case Report: Minocycline-induced drug reaction with eosinophilia and systemic symptoms syndrome: a case report and literature review

Drug Reaction with Eosinophilia and Systemic Symptoms: an update on pathogenesis

Analysis of a case of drug-induced hypersensitivity syndrome and review of related clinical progress

Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS)/Drug-Induced Hypersensitivity Syndrome (DiHS)—Readdressing the DReSS